Page last updated: 2024-08-23

etoposide and lovastatin

etoposide has been researched along with lovastatin in 15 studies

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19901 (6.67)18.7374
1990's1 (6.67)18.2507
2000's6 (40.00)29.6817
2010's7 (46.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Ekins, S; Williams, AJ; Xu, JJ1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Rodman, MJ1
Bardeleben, RV; Dunkern, T; Fritz, G; Kaina, B1
Kang, WK; Ko, U; Lee, I; Park, C1
Damrot, J; Epe, B; Fritz, G; Kaina, B; NĂ¼bel, T; Roos, WP1
Kenna, T; Mattarollo, SR; Nicol, AJ; Nieda, M1

Reviews

1 review(s) available for etoposide and lovastatin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

14 other study(ies) available for etoposide and lovastatin

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
[Isolation of drug-resistant mutant cells].
    Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 1991, Volume: 36, Issue:13

    Topics: Alkylating Agents; Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Aphidicolin; Camptothecin; Cell Separation; Drug Resistance; Etoposide; Humans; Hydroxamic Acids; Lovastatin; Monensin; Nucleic Acids; Teniposide; Toxins, Biological; Tunicamycin

1991
What to expect from the newest drugs.
    RN, 1988, Volume: 51, Issue:3

    Topics: Adrenergic beta-Antagonists; Anti-Bacterial Agents; Antiemetics; Dronabinol; Drug Therapy; Etoposide; Flurbiprofen; Follicle Stimulating Hormone; Humans; Interleukin-2; Ipratropium; Lovastatin; Prazosin; Propanolamines; Streptokinase; Tissue Plasminogen Activator; Tranexamic Acid

1988
The HMG-CoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide.
    International journal of molecular medicine, 2002, Volume: 10, Issue:4

    Topics: Animals; Apoptosis; Cell Cycle; CHO Cells; Comet Assay; Cricetinae; DNA; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin

2002
Differential effects of RhoA signaling on anticancer agent-induced cell death.
    Oncology reports, 2005, Volume: 13, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle; Cell Death; Drug Resistance, Neoplasm; Etoposide; Fluorouracil; Humans; Lovastatin; Paclitaxel; rhoA GTP-Binding Protein; Signal Transduction; Transfection; Tumor Cells, Cultured; Vincristine

2005
Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide.
    British journal of pharmacology, 2006, Volume: 149, Issue:8

    Topics: Antibiotics, Antineoplastic; Antimutagenic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Survival; DNA Damage; DNA Replication; Doxorubicin; Drug Resistance, Neoplasm; Endothelial Cells; Etoposide; Fibroblasts; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase II Inhibitors

2006
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
    Cancer immunology, immunotherapy : CII, 2007, Volume: 56, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Concanavalin A; Cytotoxicity, Immunologic; Diphosphonates; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Genes, T-Cell Receptor delta; Genes, T-Cell Receptor gamma; Humans; Imidazoles; Interferon-gamma; Lovastatin; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasms; Perforin; Pore Forming Cytotoxic Proteins; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Urinary Bladder Neoplasms; Vincristine; Zoledronic Acid

2007